Aβ42/Aβ40 and Aβ42/Aβ38 ratios are associated with measures of gait variability and activities of daily living in mild Alzheimer’s disease: A pilot study

Manuscript Number: 

18-0622R1

Author(s): 
Brook Galna, Robert Howard, Ivan Koychev, Jennifer Lawson, Simon Lovestone, Paresh Malhotra, Basil Ridha, Craig W. Ritchie, Lynn Rochester, James B. Rowe, Alan Thomas, Giovanna Zamboni, Henrik Zetterberg

Disclosures

Brook Galna

  • Nothing to Disclose

Robert Howard

  • Nothing to Disclose

Ivan Koychev

  • Nothing to Disclose

Jennifer Lawson

  • Nothing to Disclose

Simon Lovestone

  • Consulting Fees:
    Merck - single consultancy meeting. payment less than €3000 SomaLogic - unpaid member of advisory board
    Lecture Fees:
    Eiasi - single occassion, payment less than €2000
    Grants
    • Agency: 
      EU-IMI
      Dates: 
      2013 to date
    • Agency: 
      J&J
      Dates: 
      2015 to date
    • Agency: 
      Astra Zeneca
      Dates: 
      2016 to date

Paresh Malhotra

  • Nothing to Disclose
    Grants
    • Agency: 
      Shire Pharmaceuticals ('Drugs only' Grant
      Dates: 
      2015

Basil Ridha

  • Lecture Fees:
    I gave a talk on "bedside cognitive assessment" at a national movement disorders meeting in London in March 2018 sponsored by Bial Pharmaceuticals. The content of the talk was not related to this manuscript

Craig W. Ritchie

  • Nothing to Disclose

Lynn Rochester

  • Consulting Fees:
    BIOGEN advisory board on the use of wearable sensors to monitor movement

James B. Rowe

  • Consulting Fees:
    Asceneuron, scientific advisory group.
    Lecture Fees:
    GE Healthcare, lecture honorarium 2018
    Grants
    • Agency: 
      AZ-Medimmune
      Dates: 
      2016-2019
    • Agency: 
      Janssen
      Dates: 
      2017-19

Alan Thomas

  • Nothing to Disclose

Giovanna Zamboni

  • Nothing to Disclose

Henrik Zetterberg

  • Nothing to Disclose